Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Advanced Adenocarcinoma
DRUG: BA3182
Part 1: Assess dose limiting toxicity as defined in the protocol, Phase 1 Part 1: Safety Profile of BA3182, Up to 24 months|Part 1: Assess maximum tolerated dose as defined in the protocol, Phase 1 Part 1: Safety Profile of BA3182, Up to 24 months|Part 2: Confirmed overall response rate (ORR) per RECIST v1.1, Phase 1 Part 2: Antitumor activity of BA3182, Up to 24 months
Confirmed overall response rate (ORR) per RECIST v1.1, Phase 1 Part 1: Antitumor activity of BA3182, Up to 24 months|Confirmed best overall response best overall response (BOR), Phase 1: Antitumor activity of BA3182, Up to 24 months|Confirmed duration of response (DOR), Phase 1: Antitumor activity of BA3182, Up to 24 months|Confirmed progression-free survival (PFS), Phase 1: Antitumor activity of BA3182, Up to 24 months|Confirmed disease control rate (DCR), Phase 1: Antitumor activity of BA3182, Up to 24 months|Confirmed time to response (TTR), Phase 1: Antitumor activity of BA3182, Up to 24 months|Confirmed overall survival (OS), Phase 1: Antitumor activity of BA3182, Up to 24 months|Confirmed percent change from baseline in target lesion sum of diameters., Phase 1: Antitumor activity of BA3182, Up to 24 months|Area under the plasma concentration versus time curve (AUC), Phase 1: Pharmacokinetics of BA3182, Up to 24 months|Peak Plasma Concentration (Cmax) Phase 1: Pharmacokinetics, Phase 1: Pharmacokinetics of BA3182, Up to 24 months|Incidence of anti-drug antibody (ADAs) to BA3182 Phase 1: Pharmacokinetics Phase 1: Immunogenicity, Phase 1: Immunogenicity of BA3182, Up to 24 months|Incidence of neutralizing antibodies (nAbs) to BA3182., Phase 1: Immunogenicity of BA3182, Up to 24 months
This is a multi-center, open-label, Phase 1 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3182 in patients with advanced adenocarcinoma.